Literature DB >> 17043887

MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children.

Anna Wasilewska1, Grzegorz Zalewski, Lech Chyczewski, Walentyna Zoch-Zwierz.   

Abstract

The study was aimed at investigating the association between MDR-1 genetic polymorphisms [C1236T, G2677T(A), C3435T] and parameters describing the clinical course and treatment response of childhood steroid-responsive nephrotic syndrome (SRNS). Three MDR-1 genetic markers were analyzed in 108 children diagnosed with SRNS and in 135 healthy controls with neither allergic nor renal disease. All subjects were genotyped by PCR-restriction fragment length polymorphism (RFLP) analysis, and an EM algorithm-based analysis was utilized to estimate haplotype frequencies. As expected, there was no difference in genotypic and allelic distribution between and among SRNS patients and healthy children. However, all individual polymorphisms were strongly associated with time to response to initial prednisone therapy. The frequencies of the mutated alleles were higher in late responders (time to remission: >7 days) to oral prednisone (0.53, 0.52,0.66) than in early responders (time to remission: <7 days; 0.24, 0.19, 0.32), with all p values <0.001 for positions 1236, 2677 and 3435, respectively). Odds ratios (ORs) reflecting the strength of the associations were as follows: 6.79 (95% CI:1.96- 23.54) for 1236 T/T, 13.7 (95% CI:2.78-67) for 2677 T/T and 9.92 (95% CI: 3.01-32.71) for 3435 T/T as compared to the respective-wild type homozygotes. The TTT haplotype was similarly found to be significantly associated with late oral steroid response (0.49 vs. 0.19, p=0.0003). Variants 1236T, 2677TA and 3435T identify patients that respond slower to oral prednisone. Although the functional properties of the substitutions investigated here are still to be determined, our findings may be a small step toward the optimization of immunosuppressive therapy in SRNS children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043887     DOI: 10.1007/s00467-006-0275-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  35 in total

Review 1.  Pharmacogenetics of drug transporters and its impact on the pharmacotherapy.

Authors:  Toshiyuki Sakaeda; Tsutomu Nakamura; Katsuhiko Okumura
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

2.  Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes.

Authors:  G Raghu; S W Park; I B Roninson; E B Mechetner
Journal:  Exp Hematol       Date:  1996-08       Impact factor: 3.084

3.  Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.

Authors:  Shizuyo Tsujimura; Kazuyoshi Saito; Shingo Nakayamada; Kazuhisa Nakano; Yoshiya Tanaka
Journal:  Arthritis Rheum       Date:  2005-06

4.  Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation.

Authors:  Mindy He Magee; Robert A Blum; Christian D Lates; William J Jusko
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

5.  P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes.

Authors:  R J Farrell; M J Menconi; A C Keates; C P Kelly
Journal:  Aliment Pharmacol Ther       Date:  2002-05       Impact factor: 8.171

Review 6.  P-glycoprotein in autoimmune diseases.

Authors:  Yvonne Richaud-Patin; Elena Soto-Vega; Juan Jakez-Ocampo; Luis Llorente
Journal:  Autoimmun Rev       Date:  2004-03       Impact factor: 9.754

7.  Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1982-10       Impact factor: 4.406

8.  Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors: 
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

9.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Authors:  Deanna L Kroetz; Christiane Pauli-Magnus; Laura M Hodges; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Elaine J Carlson; Ira Herskowitz; Kathleen M Giacomini; Andrew G Clark
Journal:  Pharmacogenetics       Date:  2003-08

Review 10.  The MDR1 (ABCB1) gene polymorphism and its clinical implications.

Authors:  Ichiro Ieiri; Hiroshi Takane; Kenji Otsubo
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more
  19 in total

1.  Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome.

Authors:  Chiara Oretti; Sara Marino; Fabio Mosca; Maria Rosa Colnaghi; Sara De Iudicibus; Ilenia Drigo; Gabriele Stocco; Fiora Bartoli; Giuliana Decorti; Sergio Demarini
Journal:  Eur J Clin Pharmacol       Date:  2009-01-29       Impact factor: 2.953

2.  Genetic variability and haplotype profile of MDR1 in Saudi Arabian males.

Authors:  Abdullah M Al-Mohizea; Khalid M Alkharfy; Khawla M Bagulb; Amal M Alghamdi; Fahad I Al-Jenoobi; Saleh Al-Muhsen; Rabih Halwani; Mohammad Khalid Parvez; M Khalid Parvez; Mohammed S Al-Dosari
Journal:  Mol Biol Rep       Date:  2012-10-07       Impact factor: 2.316

3.  Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study.

Authors:  Anna Carmela P Sagcal-Gironella; Catherine M T Sherwin; Rommel G Tirona; Michael J Rieder; Hermine I Brunner; Alexander A Vinks
Journal:  Clin Ther       Date:  2011-10-07       Impact factor: 3.393

4.  Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome.

Authors:  Yee-Hsuan Chiou; Lin-Yu Wang; Tzu-Hui Wang; Shiao-ping Huang
Journal:  Pediatr Nephrol       Date:  2012-05-20       Impact factor: 3.714

5.  Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome.

Authors:  Hyun Jin Choi; Hee Yeon Cho; Han Ro; So Hee Lee; Kyung Hee Han; Hyunkyung Lee; Hee Gyung Kang; Il Soo Ha; Yong Choi; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2011-05-08       Impact factor: 3.714

6.  Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.

Authors:  Chise Kodaira; Mitsushige Sugimoto; Masafumi Nishino; Mihoko Yamade; Naohito Shirai; Shinya Uchida; Mutsuhiro Ikuma; Shizuo Yamada; Hiroshi Watanabe; Akira Hishida; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2009-02-24       Impact factor: 2.953

Review 7.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Authors:  King Leung Fung; Michael M Gottesman
Journal:  Biochim Biophys Acta       Date:  2009-03-11

Review 8.  Pharmacogenetics and pharmacogenomics in rheumatology.

Authors:  Zoltán Szekanecz; Bertalan Meskó; Szilard Poliska; Andrea Váncsa; Szilvia Szamosi; Edit Végh; Enikö Simkovics; Judit Laki; Júlia Kurkó; Timea Besenyei; Katalin Mikecz; Tibor T Glant; László Nagy
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

9.  MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results.

Authors:  Martina Cizmarikova; Ludmila Podracka; Lucia Klimcakova; Viera Habalova; Andrej Boor; Jan Mojzis; Ladislav Mirossay
Journal:  Med Sci Monit       Date:  2015-01-06

10.  Screening for urinary biomarkers of steroid-resistant nephrotic syndrome in children.

Authors:  Yongqi Bai; Wenjun Liu; Qulian Guo; Yan Zou
Journal:  Exp Ther Med       Date:  2012-12-21       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.